

Contact:

Luanne Rodgers
Organ Recovery Systems
847-824-2600
lrogers@organ-recovery.com

Chris Stamm or Sherry Feldberg
Schwartz Communications, Inc.
781-684-0770
ors@schwartz-pr.com

**ORGAN RECOVERY SYSTEMS INTRODUCES LIFEPORT™ KIDNEY
TRANSPORTER TO ASIAN MEDICAL COMMUNITY AT NEPHROASIA 2004**

*New Device May Offer Significant Improvement over
Static Storage of Kidneys for Transplantation*

SINGAPORE—FEBRUARY 9, 2004—Organ Recovery Systems, a developer of technologies and services to improve the quality and quantity of organs, cells, and tissues for transplantation, today announced it will introduce the LifePort™ Kidney Transporter to the Asian nephrology and transplant communities for the first time at NephroAsia 2004. Asia's Premier Nephrology Congress, NephroAsia is a forum for renal professionals to discover and discuss breakthrough advances in nephrology research and clinical practice. The conference will take place at the Suntec Singapore International Convention and Exhibition Center in Singapore from February 9 – 12. Conference attendees can visit Organ Recovery Systems at booth E01 for a live demonstration of this revolutionary device.

Portable, durable, and easy to use, the LifePort™ Kidney Transporter is the first in a new generation of mobile perfusion devices specifically designed to establish a continuum of organ care that spans the critical time between recovery and transplantation. The LifePort™ Kidney Transporter provides a new high-tech alternative to the conventional static method of organ storage and transportation—a cooler filled with ice. Perfusion is the gentle pumping of an organ with a physiologic solution as a pre-treatment for transplantation. The revolutionary device received clearance from the U.S. Food & Drug Administration (FDA) in August 2003 to be marketed in the United States.

The LifePort Kidney Transporter gently perfuses, or pumps, the kidney with a cold liquid solution to improve its condition before transplantation. Research shows that machine perfusion can safely prolong the average cold storage time for kidneys from the current 18 hours to 35 hours or more. With the extra time afforded by this technology, kidney transplants may soon become more elective-style as opposed to emergency-style procedures, resulting in improved outcomes and decreased hospital costs. The device also provides critical data to monitor and evaluate kidneys during transport. As a result, physicians and organ procurement professionals can better ensure the proper match between donor and recipient. Most importantly, several recent scientific papers suggest that machine perfusion may help enable the successful recovery for transplant of so called expanded criteria kidneys which are otherwise generally not used.

“We expect the LifePort Kidney Transporter to help reduce the global imbalance in the number of people on waiting lists for kidneys and the number of organs available for transplant. NephroAsia 2004 is the ideal setting to introduce LifePort in Asia as those attending welcome advances in nephrology and will appreciate the potential of the LifePort Kidney Transporter to expand the number of organs available and improve transplant outcomes,” said David Kravitz, CEO of Organ Recovery Systems. “Our company looks forward to further refining its technology to introduce new, life-saving devices for the global transplant community. LifePort Perfusion Transporters for liver, pancreas, and heart are in late-stage development,” Kravitz added.

About Organ Recovery Systems

Organ Recovery Systems is a privately held company developing technologies and services to improve the quality and quantity of organs, tissues, and cells for transplantation. The company’s flagship medical device, the FDA-cleared LifePort™ Kidney Transporter, is a mobile perfusion device that establishes a continuum of organ care spanning the critical time between recovery and transplantation. LifePort devices for the heart, liver and pancreas are in development, and the company is creating methods to improve the preservation and assessment of donated pancreas for improved yield and quality of Islet cells for transplant. The LifePort was named one of the top 100 breakthrough technologies by *Popular Science* in its 2003 Best of What’s New Awards.

Organ Recovery Systems is organized into three operating groups: the Perfusion Services Group helps transplant centers and organ procurement organizations (OPOs) by employing proprietary perfusion techniques for evaluation and therapy of traditional, expanded criteria, and nonheartbeating donor kidneys prior to transplant; the Medical Devices Group develops perfusion-based devices to improve the preservation, assessment, and treatment of organs for transplantation; and the Charleston Research Center develops new technologies for cell and tissue preservation and evaluation while conducting basic and applied research to support the company’s platform of organ therapy products. For more about Organ Recovery Systems visit <http://www.organ-recovery.com>.